Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.vaccine.2013.05.049 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Enhancing antibody levels and T cell activity of quadrivalent influenza vaccine by combining it with CpG HP021.
Sci Rep
December 2024
State Key Laboratory for Diagnosis, Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003, China.
Influenza virus infections are a serious danger to people's health worldwide as they are responsible for seasonal flu outbreaks. There is an urgent need to improve the effectiveness and durability longevity of the immune response to influenza vaccines. We synthesized the CpG HP021 and examined the impact of it on the immune response to an influenza vaccine.
View Article and Find Full Text PDFInfluenza vaccination for children in Europe: The health of every child matters.
Vaccine
December 2024
Scientific Advisor and Emeritus Director, National Influenza Centre, Valladolid, 47010, Spain.
Long-term multi-systemic complications following SARS-CoV-2 Omicron and Delta infection in children: a retrospective cohort study.
Clin Microbiol Infect
December 2024
National Centre for Infectious Diseases, Singapore; Duke-NUS Graduate Medical School, National University of Singapore, Singapore; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Ministry of Health, Singapore; Saw Swee Hock School of Public Health, National University of Singapore, Singapore.
Objectives: Most studies on long-term sequelae of SARS-CoV-2-infection in children were conducted pre-Omicron and pre-dated vaccination rollout. We examined long-term risk of new-incident multi-systemic sequelae after SARS-CoV-2 Delta/Omicron infection in a multi-ethnic Asian pediatric population.
Methods: Retrospective cohort study of Singaporean children aged 1- 17 years infected during Delta/Omicron BA.
Moderate effectiveness of influenza vaccine in outpatient settings: A test-negative study in Beijing, China, 2023/24 season.
Vaccine
December 2024
Institute for Infectious Diseases and Endemic Diseases Prevention and Control, Beijing Center for Disease Prevention and Control, Beijing, China; Beijing Research Center for Respiratory Infectious Diseases, Beijing, China. Electronic address:
Introduction: The objective of our study was to estimate the influenza vaccine effectiveness for 2023/24 epidemic of co-circulating influenza A(H3N2) and B(Victoria) viruses in Beijing, China.
Methods: The surveillance-based study included all swabbed patients through influenza virological surveillance in Beijing, between October 2023 and March 2024. A Test-Negative Design(TND) was used to estimate influenza vaccine effectiveness(VE) against medically- attended laboratory-confirmed influenza in outpatient settings, also calculated the influenza vaccination rate(IVR).
Impact of influenza immune imprinting on immune responses to subsequent vaccinations in mice.
Vaccine
December 2024
Center for Inflammation, Immunity & Infection, Georgia State University Institute for Biomedical Sciences, 100 Piedmont Ave SE, Atlanta, GA 30303, USA. Electronic address:
The immune memory imprinted during an individual's initial influenza exposure (influenza imprinting) has long-lasting effects on the host's response to subsequent influenza infections and vaccinations. Here, we investigate how different influenza virus imprinting impacts the immune responses to subunit, inactivated virus, and protein-based nanoparticle vaccines in Balb/c mice. Our results indicated a phylogenetic distance-dependent effect of influenza imprinting on subunit hemagglutinin (HA) or formalin-inactivated (FI) virus vaccine immunizations.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!